Alkem Laboratories

Alkem Laboratories set up its research and development facility for ANDA development at Taloja in 2003. In 2006 anti-infective drug Taxim of Alkem became the first anti-infective drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India. In 2014 Clavam another drug from Alkem crossed the 2,000 million marks in terms of domestic sales in India.

In 2007 the company filed its first ANDA for the drug Amlodipine which was approved in 2009. Alkem has developed a portfolio of 705 branded generic drugs, with 13 of the brands featured among the top 300 brands in India for the fiscal year 2015 and a portfolio of 705 brands in India in the six months ended 30 September 2015. Alkem has 21 manufacturing facilities, 19 in India and 2 in the US. 5 of the facilities are US FDA, TGA, UK MHRA approved.

United States

Being the focal point of our international operations, we manufacture and supply a wide range of generics and branded formulations in the United States. Our primary subsidiary, ascend is ranked amongst the fastest-growing companies in terms of generic drugs sales.

Our other assets include Norac Pharma in California for API manufacturing and a finished dosage manufacturing facility in St Louis, Missouri for producing a complete range of formulations of controlled substances.

Our commitment to research has led us to cumulatively file over 144 ANDAs with the US FDA. Our products are available at major pharmacy chains, wholesalers, managed care companies, distributors, and pharmaceutical retailers.

AUSTRALIA

Pharmacor is Alkem’s subsidiary in Australia. It features amongst the fast-growing generic companies in Australia. Pharmacor is an integral part of Alkem’s international business.

In the recent past, Pharmacor has been associated with several first-launch generics that have contributed significantly to the company’s growth. With a product portfolio consisting of around 200 SKUs and many more in the pipeline; Pharmacor is earmarked to achieve greater milestones in the near future.